GUMULEC, Jaromír, Michaela FOJTŮ, Martina RAUDENSKÁ, Markéta SZTALMACHOVÁ, Anna SKOTÁKOVÁ, Jana VLACHOVA, Sylvie SKALICKOVA, Lukáš NEJDL, Pavel KOPEL, Lucia KNOPFOVÁ, Vojtech ADAM, Rene KIZEK, Marie STIBOROVA, Petr BABULA and Michal MASAŘÍK. Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2014, vol. 15, No 12, p. 22960-22977. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms151222960.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages
Authors GUMULEC, Jaromír (203 Czech Republic, belonging to the institution), Michaela FOJTŮ (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Markéta SZTALMACHOVÁ (203 Czech Republic, belonging to the institution), Anna SKOTÁKOVÁ (203 Czech Republic, belonging to the institution), Jana VLACHOVA (203 Czech Republic), Sylvie SKALICKOVA (203 Czech Republic), Lukáš NEJDL (203 Czech Republic), Pavel KOPEL (203 Czech Republic), Lucia KNOPFOVÁ (203 Czech Republic, belonging to the institution), Vojtech ADAM (203 Czech Republic), Rene KIZEK (203 Czech Republic), Marie STIBOROVA (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution).
Edition International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2014, 1422-0067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.862
RIV identification code RIV/00216224:14110/14:00078586
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/ijms151222960
UT WoS 000346797400083
Keywords in English Apoferritin; Cancer; Cardiotoxicity; Doxorubicin; Encapsulation; Liposome; Modification
Tags EL OK
Tags Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 24/4/2015 13:47.
Abstract
Doxorubicin is an effective chemotherapeutic drug, however, its toxicity is a significant limitation in therapy. Encapsulation of doxorubicin inside liposomes or ferritin cages decreases cardiotoxicity while maintaining anticancer potency. We synthesized novel apoferritin- and liposome-encapsulated forms of doxorubicin (“Apodox” and “lip-8-dox”) and compared its toxicity with doxorubicin and Myocet on prostate cell lines. Three different prostatic cell lines PNT1A, 22Rv1, and LNCaP were chosen. The toxicity of the modified doxorubicin forms was compared to conventional doxorubicin using the MTT assay, real-time cell impedance-based cell growth method (RTCA), and flow cytometry. The efficiency of doxorubicin entrapment was 56% in apoferritin cages and 42% in the liposome carrier. The accuracy of the RTCA system was verified by flow-cytometric analysis of cell viability. The doxorubicin half maximal inhibition concentrations (IC50) were determined as 170.5, 234.0, and 169.0 nM for PNT1A, 22Rv1, and LNCaP, respectively by RTCA. Lip8-dox is less toxic on the non-tumor cell line PNT1A compared to doxorubicin, while still maintaining the toxicity to tumorous cell lines similar to doxorubicin or epirubicin (IC50 = 2076.7 nM for PNT1A vs. 935.3 and 729.0 nM for 22Rv1 and LNCaP). Apodox IC50 was determined as follows: 603.1, 1344.2, and 931.2 nM for PNT1A, 22Rv1, and LNCaP.
PrintDisplayed: 29/7/2024 22:04